Eli Lilly to Buy Merida Biosciences for Up to $2.875 Billion — Update
By Colin Kellaher
Eli Lilly remains on a shopping spree, agreeing to pay up to $2.875 billion in cash for biotechnology company Merida Biosciences in a deal that bolsters the drugmaker's immunology portfolio.
Eli Lilly on Monday said privately held Merida is advancing a new class of precision therapeutics for serious autoimmune and allergic diseases, with its lead program in Phase 1 development for Graves' disease and thyroid eye disease.
The Merida deal continues a spate of acquisitions by the Indianapolis company, which is flush with cash from its market-leading weight-loss-drug franchise.
Eli Lilly last month struck a deal to buy mental-health-focused AtaiBeckley for an initial $2.8 billion and in late May agreed to acquire three vaccine developers in deals valued at up to nearly $4 billion combined.
Earlier in the year, the company struck deals each valued at less than $10 billion to buy cancer biotech Kelonia Therapeutics, blood-cancer focused Ajax Therapeutics, sleep-drug maker Centessa Pharmaceuticals, genetic-medicine biotechnology company Orna Therapeutics and biotech Ventyx Biosciences.
Eli Lilly said the Merida deal consideration includes an undisclosed upfront cash payment, along with contingent milestone payments.
Merida, based in Cambridge, Mass., launched last year with $121 million in Series A financing was co-led by Bain Capital Life Sciences, BVF Partners and Third Rock Ventures.
The transaction is slated to close by the end of the year.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 31, 2026 07:33 ET (11:33 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
What’s Ahead for Stocks This Quarter—and Where to Invest
Are TIPS ETFs the Best Way to Fight Inflation?
10 Best Blue-Chip Stocks to Buy for the Long Term
United States